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Abstract 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused 
by an expanded CAG repeat. Though symptom onset commonly occurs at midlife and inversely 
correlates with the CAG repeat expansion, age at clinical onset and progression rate are 
variable. In the present study we investigated the relationship between leukocyte telomere 
length (LTL) and HD development. LTL was measured by real-time PCR in manifest HD 
patients (HD, n=62), pre-manifest HD patients (pre-HD, n=38), and age-matched controls (n= 
76). Significant LTL differences were observed between the three groups (p< 0.0001), with 
LTL values in the order: HD <pre-HD <controls. The relationship between LTL and age was 
different in the three groups. An inverse relationship between mean LTL and CAG repeat 
number was found in the pre-HD (p=0.03). The overall data seem to indicate that after age 30 
years, LT begins to shorten markedly in pre-HD patients according to CAG number and 
increasing age, up to the values observed in HD. This very suggestive picture allowed us to 
hypothesize that in pre-manifest HD, LTL could be a measure of time to clinical HD onset.  The 
possible use of LTL as a reliable biomarker to track HD development and progression was 
evaluated and discussed. 
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1. Introduction 
Huntington’s disease (HD) is an autosomal dominant, progressive neurodegenerative 
disorder caused by a CAG trinucleotide repeat expansion in the first exon of the HTT gene 
encoding huntingtin (HTT). The mutant protein contains an expanded polyglutamine sequence 
(poly-Q) that confers a toxic gain of function and results in neurodegeneration. The disease is 
fully penetrant in individuals with ≥ 40 repeats, with onset of motor symptoms in mid-age, often 
in the fourth or fifth decade. Overall the age of onset is inversely correlated with the size of the 
CAG repeat expansion, but actually the age of clinical onset, rate of disease progression, and 
severity of symptoms vary widely among individuals. CAG repeat length accounts for about 
56% of the variation in age at clinical onset within a range of 40 to 55 CAG repeats. Since the 
remaining variance in age at motor onset is not explained by the length of the CAG repeat, it 
cannot be used to accurately predict when symptoms will occur. This residual variance is 
probably due to genetic, stochastic, and environmental factors [1-3]. The challenge is to identify 
objectively measurable peripheral biomarkers related to CAG repeat length in a statistical tool 
to predict age of onset and disease progression.  
Human telomeres consist of repeated TTAGGG nucleotide sequences located at the 
ends of chromosomes where they protect them against from DNA damage. During DNA 
replication, telomeres shorten progressively with repeated cell divisions due to the inability of 
DNA polymerase to replicate the 3′ end of the DNA strand. A cellular multi-protein complex, 
called telomerase, counteracts telomere shortening [4,5]. Usually present in the early stages of 
embryonic development, its activity is silenced in several human somatic tissues immediately 
after birth [6]. As a consequence, in the telomeres shorten progressively in the replicating cells 
of adult tissues (including skin, kidney, liver, blood vessels, and peripheral leukocytes); this 
phenomenon is thought to indicate cellular age and reflect an organism’s biological age [7-9].  
By virtue of tissue availability, measurement of leukocyte telomere length (LTL) is 
widely used as a marker of overall telomere length assuming that, within a given individual, the 
TL of various tissue types is strongly correlated [10]. Epidemiological studies have provided 
evidence for the hypothesis that leukocyte telomere shortening is associated with aging 
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[7,8,9,11] and with age-related chronic diseases (cardiovascular and metabolic diseases, cancer), 
although some inconsistencies have been observed [11-13]. LTL was also investigated in 
connection with such neurodegenerative diseases as Alzheimer’s disease (AD), Parkinson’s 
disease (PD), and HD. Despite some discordant results, shorter leukocyte telomeres were 
frequently found in association with cognitive decline/dementia, AD and its prodromal state, 
MCI (mild cognitive impairment) [14-16]. Recently, we were able to identify a significant 
progressive leukocyte telomere reduction in patients with MCI and AD patients as compared to 
controls [17]. This finding suggests that LTL measurement could provide a useful marker to 
follow dementia progression from its prodromal stages (MCI) to manifest AD. Studies on 
telomere length in PD patients showed no significant evidence of shorter telomere length [18].  
In contrast, in the only study carried out on HD to our knowledge, significantly shorter LTL was 
observed in manifest HD patients as compared to controls [19].  
AD and HD share several common features, including neuronal loss, accumulation of 
aggregated and misfolded proteins, and cognitive decline. On account of this, we thought it 
interesting to determine whether LTL is reduced in manifest HD patients and to investigate LTL 
in pre-manifest HD, i.e., at the disease stage in which, as observed in the AD prodromal stage 
(MCI), telomere shortening presumably begins and progresses to reach LTL values observed in 
manifest HD. If so, the telomere measurement could be a useful parameter to follow the 
development of the disease. Unlike persons with MCI in whom the course of the disease 
towards AD is uncertain, HD patients with CAG repeat expansion in the pre-manifest stage will 
inexorably develop the disease, although the age at disease onset is highly variable.  Indeed, the 
inverse relationship between HD age at onset and the number of CAG repeats, is stronger for 
the alleles with 60 repeats or higher but weaker for the most frequent HD alleles (55 or fewer) 
[1]. Some models have been developed to estimate the years until onset in mutation carriers on 
the basis of age and CAG repeat length [20], but their usefulness may be limited by the 
complexity of the HD clinical phenotype, to whose manifestation other genetic and 
environmental factors may take part [21]. In this context, the search for reliable biological 
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markers that can contribute to predict age of onset and disease progression is crucial in both 
genetic counseling and trials of disease-modifying drugs that could delay disease onset.   
Here, we analyzed LTL in a sample of pre-manifest (pre-HD) and manifest HD (HD) 
patients. We then compared LTL with relevant disease parameters (number of repeats, age at 
disease onset, disease duration) to gain a clearer picture of the relationships between telomere 
length and HD development and progression. Measurement of LTL in HD mutation carriers at 
different stages of the disease (pre-manifest and manifest with different disease duration) could 
prove to be a useful non-invasive tool to predict clinical onset in pre-manifest HD patients and 
disease progression in manifest HD patients.   
2. Materials and Methods 
2.1 Subjects 
The study population consisted of 62 unrelated patients with clinical diagnosis of HD, 
38 pre-manifest mutation carriers, and 76 age-matched control subjects collected over years at 
the Institute of Translational Pharmacology, National Research Council, referred from various 
neurological centres of Rome (Italy). Diagnosis was performed by an experienced HD 
neurologist on the basis of the Unified Huntington's Disease Rating Scale (UHDRS) using a 
Total Motor Score ≥ 4, for the diagnosis of HD [22].  Among HD patients about 50% were at an 
early disease stage, and 50% at a moderate disease stage [22]. 
Clinical data are reported in Table 1. Age considered for the analysis was the age at the 
time of blood collection.  Age at onset was available only for 40 patients and was estimated as 
the age at which motor and/or cognitive symptoms first occurred. Control subjects were 
recruited from among patients’ healthy relatives and spouses, who were suitable to be matched 
for age and gender and agreed to participate in the study. Written, informed consent was 
obtained from all participants. The protocol for the collection of DNAs for research purposes 
was approved by the institutional ethics committees according to the principles expressed in the 
Declaration of Helsinki.  
2.2 Laboratory Methods 
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Venous blood was drawn in EDTA from all subjects after overnight fasting. Genomic 
DNA was extracted from whole blood using the salting out method described by Miller et al. 
[23].  HD molecular diagnosis was performed in duplicate by PCR amplification with primers 
HD1/HD3 [24]; DNA fragments were analyzed by capillary electrophoresis. The results were 
confirmed by triplet repeat primed PCR (TP PCR) [25]. 
The average (of triplicate) telomere length in leukocytes was measured by monoplex 
real-time PCR quantitative analysis (monoplex qPCR) on a 7300 real-time PCR instrument 
(Applied Biosystems). This method allows the determination of the number of copies of 
telomeric repeats (T) compared to a single copy gene (S) used as a quantitative control (T/S 
ratio) [26]. The telomere and single-copy gene β-globin (HGB) were analyzed on the same plate 
in order to reduce inter-assay variability. DNA (35 ng) was amplified in a total volume of 20 μl 
containing 10 μl of SYBER Select Master Mix (Applied Biosystems); primers for telomeres and 
the single-copy gene were added to final concentrations of 0.1 μM (Tel Fw), 0.9 μM (Tel Rev) 
and 0.3 μM (HGB Fw), 0.7 μM (HGB Rev), respectively. The primer sequences were: Tel Fw 
5′-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-3′; Tel Rev 5′-
GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT-3′; HGB Fw 5′-
GCTTCTGACACAACTGTGTTCACTAGCAAC-3′; HGB Rev 5′-
CACCACCAACTTCATCCACGTTCACCTTGC-3′ [26]. The enzyme was activated at 95°C 
for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. In addition, two standard 
curves (one for HGB and one for telomere reactions), were prepared for each plate using a 
reference DNA sample (Control Genomic Human DNA, Applied Biosystems) diluted in series 
(dilution factor of 2) to produce 5 concentrations of DNA ranging from 50 to 6.25 ng in 20 µL. 
Measurements were performed in triplicate and are reported as T/S ratio relative to the 
calibrator sample to allow comparison across runs. Replicate assays of same sample were 
carried out to calculate the interassay variation. The average standard deviation as calculated by 
measuring relative T/S ratios of a sample repeated over three different assays was 4.2%. Thus, 
assuming a normal distribution, samples differing in average telomere length by as little as 8.3% 
(1.96 X SD) should be distinguishable by this method at the 95% confidence interval [26]. No 
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amplification of the negative controls with both primer sets (HGB and telomeres) used was 
observed. 
2.3 Statistical analysis 
Parametric (ANOVA) and nonparametric (Kruskal-Wallis) tests were used to compare 
the distribution of quantitative variables between pre-manifest and manifest HD patients and 
controls, and the distribution of the mean T/S ratio across age and repeat number classes. Level 
of significance was set at p < 0.05. The relationship between T/S ratio and age was evaluated by 
regression analysis. LTL was adjusted for age by regression for further analyses.  Comparison 
of the regression lines slopes was carried out by a t-test. 
The estimated age at onset was calculated according to the formula of Langbehn et al. 
[20], at different probability values, given CAG repeat number and age at blood sampling (see 
http://edwild.com/205-huntingtons-disease-conditional-onset-probability-calculator/). The time 
to clinical diagnosis was calculated as the difference between estimated onset and age at blood 
sampling. 
3. Results 
Leukocyte telomere length (LTL), expressed as T/S ratio, was measured in controls, 
pre-manifest HD, and manifest HD patients. Table 1 presents the demographic and clinical 
characteristics of the three groups. The difference in mean age between the groups (p<0.001) 
depended on the disease stage (pre-manifest and manifest) of HD patients, while the age range 
of the control sample corresponded to that of the HD patients (both pre-manifest and manifest).  
A statistically significant difference in the LTL distribution between the control group and the 
two patient groups (Fig. 1) was observed using Kruskal-Wallis test (p<0.00001). The LTL 
values showed a decreasing trend in the three groups, in the order control LTL > pre-manifest 
HD LTL >manifest HD. Post hoc pair-wise comparison showed that LTL values differed 
significantly from one another in the three groups (Fig. 1). No difference in mean LTL was 
observed between males and females in the three groups (controls: p=0.11, pre-manifest HD: 
p=0.99, manifest HD patients: p= 0.54).                 
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Linear regression analysis showed a significant negative relationship between LTL and 
age for each group (controls: y = -0.0027x + 1.06, p<0.0001; pre-manifest HD: y= -0.007x + 
1.05, p=0.0005; HD: y = -0.002x + 0.70, p=0.004) . Comparison of the regression lines slopes 
by a t-test showed that the decreasing trend for telomere length with age differed significantly 
between the pre-manifest HD group as compared with the controls (p=0.03) and with the HD 
group (p=0.02) . This was confirmed when we compared the LTL values for the different age 
classes of the three groups (Table 2). There was an apparent downward trend of LTL with 
increasing age for the controls, which began to grow at the more advanced ages (Table 2). In 
pre-manifest HD, the distribution by age class was uneven, with fewer patients of older age, as 
expected. The LTL of the very young pre-manifest HD patients (age class 20-29, LTL=0.91) 
was very similar to that reported in the age-matched controls (LTL= 0.97, p=0.46), with a sharp 
decrease after age 30. An opposite pattern of patient distribution across age classes was 
observed for manifest HD, in which the telomere length in the HD patients under 50 years was 
lower than that of the oldest controls. Only a further slight decrease in telomere length with 
increasing age was noted (Table 2). After age 30 the differences between the mean LTL values 
of the three groups were always highly significant (p<0.0001).  
After adjusting LTL for age, we analyzed the effect of CAG repeat number on LTL 
(Table 3). We noted an inverse relationship between mean LTL values and CAG repeats in the 
pre-manifest HD (p=0.03) but not in the manifest HD patients (p=0.66). This indicated that, in 
pre-manifest HD, the CAG number in the pathological range contributes to LT attrition 
independent of age.                               
We then tried to test the hypothesis that in pre-HD LTL could be related to time to 
clinical diagnosis. As actual age at onset was not available, for each pre-HD subject, we 
calculated the estimated age at onset according to the formula of Langbehn et al. [20] at 
different probability values. A significant association between LTL and estimated years to HD 
onset (grouped into classes of 10 years) was observed (Table 4). Just as an example, the results 
related to the estimated years to HD onset at different probability values (0.40,0.50,0.60, 0.70) 
are shown. A common feature is that the mean LTL is below 0.70 T/S in patients with an 
9 
 
expected onset within 10 years or earlier, which then increases steadily up about 1.0 in patients 
with an expected onset after 30 years or more. As the probability increases, so, too, the expected 
age of onset, and the relationship weakens. According to the formula, the number of patients in 
each class varies as onset age changes according to the probability value. The relationship 
between LTL and estimated years to HD diagnosis, is better shown in fig. 2, where, as an 
example, the linear positive correlation between LTL and estimated years to HD diagnosis with 
p=60% in pre- manifest HD patients is reported (y = 0.011x+0.60, p<0.00001).   
In the HD patients for whom the age of onset was known (n=40), the disease duration 
was calculated as the difference between the reported age of onset and the age at blood 
sampling. No relationship was observed between disease duration for the HD patients and LTL 
adjusted for age (p =0.77) (Table 5), suggesting that no further major telomere attrition occurs 
after clinical HD onset.  
4.Discussion 
We investigated LTL of HD patients at different stages of disease (pre-manifest and 
manifest HD) and compared it with LTL of healthy controls. The mean LTL differed 
significantly between the three groups, with the highest mean values noted in the controls, 
intermediate values in the pre-manifest HD, and the lowest values in the manifest HD patients. 
The difference suggests a definite relationship between telomere shortening and manifest HD 
development. The mean LTL values in the manifest HD patients were almost half those in the 
controls and slightly higher than the minimum length reported to be necessary to ensure human 
telomere protective stability in white blood cells [27]. Our finding is shared by the only other 
study that examined LTL in manifest HD patients [19], indicating that shortened LT might be a 
characteristic of HD patients. By direct comparison, the LTL of the HD patients was lower than 
that in patients with dementia [19] and AD [17], the other neurodegenerative disease in which 
LTL has been extensively investigated [14,15]. Of note is that telomere length in pre-manifest 
HD has never been examined before. In pre-manifest HD we found intermediate LTL values 
between the control and the manifest HD groups. This finding is consistent with similar 
observations in amnestic MCI, the prodromal stage of AD, and seems to indicate a common 
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model for neurodegenerative diseases in which initial telomere shortening is associated with 
initial stages of disease.  
Given the well-known inverse relationship between LTL and age in the normal 
population, we examined it in the three groups. The most relevant result concerns the 
relationship LTL/age of pre-manifest HD subjects. It emerges (Table 2) that at an early age 
(below 30 years) LTL of pre-manifest HD and controls are not different, but, after age 30, LTL 
values in the pre-manifest HD are lower than those in controls after age 80 [17]. The majority of 
the youngest manifest HD patients (age over 30 years) were noted to have very short telomeres, 
and only a slight decrease was observed in the more advanced age classes. 
The CAG repeat number was also associated with telomere shortening, but only in the 
pre-manifest HD patients, and was slightly less relevant than age.  
The overall data seem to indicate that, in pre-manifest HD patients, leukocyte telomeres 
begin to shorten gradually and markedly after age 30 years, according to advancing age and 
CAG number, up to values typically observed in manifest HD patients. According to these 
findings, LT shortening seems to be a feature of HD development, from the pre-manifest stage 
to clinical diagnosis, but the actual meaning of this observation remains to be elucidated.  An 
unresolved problem is whether shortening of leukocyte telomeres reflects a similar phenomenon 
at the neuronal level, since the absent/low level of cell turnover suggests that telomere 
shortening may not occur in the brain [10]. Studies on telomere length in brain tissue from AD 
patients, where LTL has been extensively investigated, have provided inconsistent results [28-
30]. On the other hand, LT shortening could be understood as part of HD physiopathology in 
which cell proliferation is activated by chronic systemic inflammation and oxidative stress. 
There is evidence that toxic HTT aggregates are accompanied by a neuroinflammatory state 
characterized by activation of the microglia in the brain of HD patients [31-33]. Microglia 
activation can be observed early in pre-manifest HD, followed by the release of 
proinflammatory mediators. Elevated levels of proinflammatory mediators are also found in the 
blood of HD patients, including pre-manifest carriers, and many years before disease onset. 
Microglia activation also promotes the production of reactive oxygen species (ROS), and 
11 
 
oxidative stress is known to accelerate telomere shortening [34-36].  In this context we may 
speculate that LT shortening is an indicator of the phenomena accompanying disease 
progression from the prodromal states (pre-manifest HD) to the full-blown HD.  
The length of the CAG repeat is negatively correlated with age at disease onset, 
accounting for about 50-70% of the variation in the age at onset [2]. On the basis of this 
relationship, some statistical models providing sufficiently accurate predictions have been 
proposed [20,37], although confounding factors might limit the usefulness of mathematical 
models. The identification of reliable biomarkers could greatly facilitate the prediction of 
disease onset and help in accurately tracking disease progression in pre-manifest HD. The above 
results allowed us to hypothesize that in pre-manifest HD, LTL could be a measure of time to 
clinical HD onset. To test this hypothesis, we examined the relationship between LTL and 
estimated time to clinical diagnosis calculated according to the formula of Langbehn et al. [20]. 
The relationship suggests that, in pre-manifest HD, with a probability well higher than 50%, 
LTL <0.70 T/S could be associated with an estimated time to clinical onset of 10 years or less, 
LTL < 0.80 T/S with an estimated time to clinical onset of 20 years or less, and LTL > 0.80 T/S 
with an estimated time to clinical onset of  over 20 years. At over three decades before HD 
diagnosis, LTL values are indistinguishable from those expected for young, healthy subjects, a 
finding which is in line with the previous observation (Table 3) that, in very young patients, the 
LTL of pre-manifest HD was similar to that of the controls. The present preliminary results 
seem to indicate that LTL is a possible biomarker of HD progression, although it needs to be 
accurately validated by testing the relationship between LTL and the actual age at disease onset. 
Extending the analysis to a larger sample with a well-designed follow-up study would be useful 
to verify the actual relationships between LTL, age and time to disease onset. In addition, LTL 
measurement seems to possess some of the characteristics requisite for an ideal biomarker of 
HD progression [21]. It can be obtained by blood sampling and, in our experience, LTL is 
readily quantifiable and reproducible, although numerous studies provided evidence that some 
methodological conditions (for example DNA extraction method, or master mix used) can affect 
the telomere length measurement [38-40]. The final goal is to use LTL to implement and 
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improve the prediction of age at disease onset provided by statistical model based on CAG 
repeat length. This result would be important for the development and evaluation of therapeutic 
interventions that slow or halt the progression of disease before symptoms begin.  
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Table 1 Demographic and clinical characteristics of the three groups 
. 
 
 
 
 
 
 
                    
a
n=40 
 
 
 
  
 Controls 
n=76 
Pre-manifest HD 
patients 
n=38 
Manifest HD patients 
n=62 
Age (yrs)  49.8 ± 15.1 
(range,19-74) 
35.9 ± 11.7 
 (range,19-62) 
55.3 ± 11.7 
 (range, 20-77) 
Sex (males, %) 32.4 42.1 50.8 
CAG (median and range)  / 43 (40-52) 
 
42 (40-69) 
 
Age of onset (yrs)  / / 51.0 ± 12.8 
(range, 23-76) 
a
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Table 2 LTL distribution (T/S ratio) in controls, pre-manifest HD, and HD patients by age 
class in years (median, first and third quartiles). 
                In brackets the number of subjects 
 
 
 
 
 
 
 
 
 
 
 
                    
a 
These samples were pooled for the analysis 
   
 
  
Age class 
(yrs.) 
Controls 
 
Pre-manifest HD patients  HD patients 
 
Total sample  0.92, 0.86-0.98 (76) 0.76, 0.69-0.88 (38) 0.56, 0.53-0.62 (62) 
20-29  0.97, 0.94-0.98 (10) 0.91, 0.8-1.0 (14)  0.63
a 
(1) 
30-39  0.96, 0.9-1.03 (11) 0.71, 0.68-0.80 (10) 0.63, 0.6-0.8
a 
(3)  
40-49  0.96, 0.86-1.0 (14) 0.68, 0.56-0.79 (10) 0.61, 0.55-0.66 (15) 
50-59  0.91, 0.88-1.0 (14) 
 
0.61 (2) 0.55, 0.5-0.6 (19) 
60-69  0.91, 0.84-0.96 (21) 
 
0.77 (2) 0.55, 0.53-0.56 (16) 
70-79 0.81, 0.76-0.87 (6) 
 
 0.56, 0.51-0.61 (8) 
P value 0.005  0.004  0.012  
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Table 3 Effect of CAG repeat number on LTL (T/S).  
             In brackets the number of subjects 
 
 
 
 
 
 
 
  
CAG repeats Pre-manifest HD  HD patients  
 
40 - 41 0.86 ± 0.13(13) 0.57 ± 0.05 (16) 
42-43  0.77 ± 0.13 (6) 0.56 ± 0.05(26) 
44-45 0.74 ± 0.11 (13) 0.58 ± 0.08 (14) 
≥46 0.70 ± 0.14 (6) 0.63 ± 0.12 (6) 
P value 0.03 0.66  
19 
 
 
Table 4 Relationship between mean LTL (T/S) of pre-manifest HD mutation carriers 
and estimated years to HD onset (grouped into classes of 10 years) at different 
probability values. 
Estimated years  
to HD onset 
P=0.40 P=0.50 P=0.60 P=0.70 
≤ 10 0.70 ± 0.14 (17) 0.69 ± 0.14 (16) 0.69 ± 0.15 (14) 0.66 ± 0.11 (9) 
11-20 0.80 ± 0.12 (13) 0.77 ± 0.12 (10) 0.76 ± 0.12 (11) 0.74 ± 0.12 (14) 
21-30 0.89 ± 0.13 (6) 0.89 ± 0.13 (9) 0.85 ± 0.12 (9) 0.86 ± 0.12 (9) 
>30 1.04 ± 0.08 (2) 0.99 ± 0.08 (3) 1.02 ± 0.08 (4) 0.94 ± 0.08 (6) 
P value 0.002 0.0006 0.0004 0.002 
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Table 5 Relationship between disease duration of HD patients and LTL (T/S). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Years since HD 
onset (duration) 
LTL (T/S) 
0-1 0.59 ± 0.10(10) 
2-3 0.55 ± 0.07(10) 
4-5 0.58 ± 0.10(8) 
6-10 0.58 ±0.05(8) 
>10 0.61 ± 0.07(4) 
P value 0.77 
21 
 
 
 
 
Fig. 1 Box Plot Showing the distribution of LTL (T/S ratio) in controls, pre-manifest HD, and 
HD patients.  Controls: median= 0.92, first quartile (q
1
) =0.86, third quartile (q
3
): 0.62; pre-
manifest HD: median=0.76, q
1
= 0.69, q
3
= 0.88;  HD patients: median=0.56, q
1
 = 0.53, q
3
: 
0.62. 
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Fig. 2 Relationship between LTL (T/S) and estimated years to HD diagnosis (p=60%) 
 in pre-manifest HD patients.                         
